title: Insulinlike growth factor I affects ocular development: a study of untreated and treated patients with Laron syndrome.
abstract: OBJECTIVE
  To evaluate the ocular dimensions in patients with primary growth hormone receptor insensitivity (Laron syndrome [LS]) and to study the effect of supplemental insulinlike growth factor I (IGF-I) on ocular growth.
  
  
  METHODS
  Retrospective case series.
  
  
  METHODS
  Twelve patients with LS, 8 untreated (LS group) and 4 treated (LS-T group) with supplemental IGF-I, and 30 healthy controls.
  
  
  METHODS
  Ocular dimensions and refraction were measured, and a full ophthalmologic examination was performed.
  
  
  METHODS
  Differences in the average ocular dimension data among IGF-I-treated patients, untreated ones, and controls.
  
  
  RESULTS
  The average axial length of eyes in the LS group was 21.94 mm (standard deviation [SD], 0.81). Corresponding values for the LS-T and control group eyes were 22.53 mm (SD, 1.74) and 23.20 mm (SD, 1.35) respectively. The average anterior chamber depth of eyes in the LS group was 2.55 mm (SD, 0.26). Corresponding values for eyes in the LS-T and control groups were 3.48 mm (SD, 0.09) and 3.84 mm (SD, 0.16) respectively. The average lens thickness of eyes in the LS group was 4.56 mm (SD, 0.36). Corresponding values for the LS-T and control groups were 3.77 mm (SD, 0.23) and 3.51 mm (SD, 0.25), respectively. The average corneal curvature of eyes in the LS group was 46.9 diopters (D) (SD, 2.32). Corresponding values for the LS-T and control groups were 47.6 D (SD, 2.83) and 44.4 D (SD, 1.5), respectively.
  
  
  CONCLUSIONS
  Insulinlike growth factor I seems to be an important regulator of ocular growth as documented in patients with primary growth hormone insensitivity. The mechanism of this observation should be investigated further.
authors.affiliation: Department of Ophthalmology, Jules Stein Eye Institute, David Geffen, School of Medicine at University of California, Los Angeles, California 90095-7000, USA. bourla@jsei.ucla.edu
authors.forename: Dan Haim
authors.initials: DH
authors.lastname: Bourla
authors.forename: Zvi
authors.initials: Z
authors.lastname: Laron
authors.forename: Moshe
authors.initials: M
authors.lastname: Snir
authors.forename: Pearl
authors.initials: P
authors.lastname: Lilos
authors.forename: Dov
authors.initials: D
authors.lastname: Weinberger
authors.forename: Ruth
authors.initials: R
authors.lastname: Axer-Siegel
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D005123:Eye / Q000187:drug effects* / Q000254:growth & development*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000627:therapeutic use*; D007429:Intraocular Pressure / Q000187:drug effects; D046150:Laron Syndrome / Q000188:drug therapy*; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D012029:Refraction, Ocular / Q000187:drug effects; D012189:Retrospective Studies
chemical_list: D011994:Recombinant Proteins; D007334:Insulin-Like Growth Factor I